Picture of Trilogy International Partners logo

TRL.H — Trilogy International Partners News Story

0.000.00%
ca flag iconLast trade - 00:00
TelecomsSpeculativeMicro CapContrarian

Brief: Trimel reports exclusive license deal with Endo for Natesto

Nov 24 (Reuters) - Trimel Pharmaceuticals Corp  TRL.TO : 
 * Announces exclusive license agreement with endo for Natesto 
 * Trimel will be responsible for the manufacture of Natesto and receive a tiered supply price for the product 
 * Is eligible to receive payments of up to us$165 million based on certain regulatory and sales milestones 
 * eligible to receive upfront fee of $25 mln and prepaid inventory deposit of $5 million upon closing of the deal 
 * Unit trimel biopharma srl, signed agreement providing affiliate of Endo International exclusive rights to market natesto in U.S., Mexico 
 
 * Source text for Eikon  ID:nCCN1wKjMq  
 
 * Further company coverage  TRL.TO   
 
 ((Bangalore Newsroom; +1 646 223 8780))

Recent news on Trilogy International Partners

See all news